Market news

Achieve Life Sciences is rated a 'buy' as it nears a second NDA resubmission after resolving prior manufacturing issues. Click for this ACHV stock update.

SEATTLE and VANCOUVER, British Columbia, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced that Achieve’s board of directors approved stock option grants to purchase an aggregate of 315,000 shares of its common stock and restricted stock unit (“RSU”) awards covering an aggregate of 283,000 share

By John Vandermosten, CFA NASDAQ: ACHV READ THE FULL ACHV RESEARCH REPORT Achieve Life Sciences, Inc. (NASDAQ: ACHV) reported second quarter results, introducing a number of new faces and regulatory updates since the previous financial update in May. Achieve has added new individuals to both the executive ranks and the board. The company has enhanced its commercial leadership, Chemistry,

Detailed price information for Achieve Life Sciences Inc (ACHV-Q) from The Globe and Mail including charting and trades.

Achieve Life Sciences (ACHV) has an average rating of buy and mean price target of $13.91, according

Detailed price information for Procept Biorobotics Corp (PRCT-Q) from The Globe and Mail including charting and trades.

Veteran U.S.-based CMC, supply chain, and quality leaders join Achieve as the Company continues the transition of cytisinicline finished product manufacturing to the United StatesSEATTLE and VANCOUVER, British Columbia, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve or the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced th

SEATTLE and VANCOUVER, British Columbia, July 31, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced that Achieve’s board of directors approved stock option grants to purchase an aggregate of 1,190,000 shares of its common stock and restricted stock unit (“RSU”) awards covering an aggregate of 125,000 shar

Achieve Life Sciences (NASDAQ:ACHV) held its 2026 Annual Meeting of Stockholders virtually, with Chief Executive Officer Andrew Goldberg serving as chairperson of the meeting. Goldberg called the meeting to order and said Erik Atkisson, the company’s Chief Legal Officer, would act as secretary and r